A phase I trial of combination of ublituximab + TGR-1202 + bendamustine in patients with advanced Diffuse Large B-Cell Lymphoma (DLBCL) and follicular lymphoma
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2018
At a glance
- Drugs Bendamustine (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2018 Results (n=39) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 26 Jun 2017 Results published in a TG Therapeutics media release.
- 26 Jun 2017 According to a TG Therapeutics media release, data from this trial was presented at the 22nd European Hematology Association (EHA) Annual Congress.